Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Altho...
Main Authors: | Ghaneya Al-Khadairi, Julie Decock |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/7/984 |
Similar Items
-
Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target
by: Mukulika Bose
Published: (2023-08-01) -
Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
by: Markus Albertsmeier, et al.
Published: (2020-12-01) -
Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection
by: Koon H Lee, et al.
Published: (2020-01-01) -
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
by: Ghaneya Al-Khadairi, et al.
Published: (2019-01-01) -
Meme kanserinde PRAME (preferentially expressed antigen of melanoma) ekspresyonunun prognostik önemi
by: Kubilay Dalcı, et al.
Published: (2020-09-01)